Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson’s disease
Open accessAbstract
BACKGROUND: Alterations in blood-brain barrier permeability have been proposed to represent a relevant factor contributing to Parkinson's disease progression. However, few studies have addressed this issue in patients at different stages of disease. METHODS: Albumin was measured in cerebrospinal fluid and serum samples obtained from 73 non-demented subjects with idiopathic Parkinson's disease and 47 age-matched control subjects. The albumin ratio (AR) was calculated to assess blood-cerebrospinal fluid and blood-brain barrier function. The group of patients with Parkinson's disease included 46 subjects with Hoehn-Yahr staging between 1 and 2 and 27, with a score ranging from 2.5 to 4. RESULTS: Statistically significant differences in albumin ratio were found between patients with advanced disease, and both early-stage and unaffected groups. Conversely, early-phase patients did not differ from healthy subjects. Additionally, dopaminergic treatment seems to exert a possible effect on AR values. CONCLUSIONS: Our study demonstrates that possible dysfunction of the blood-cerebrospinal fluid barrier, blood-brain barrier, or both, characterize Parkinson's disease progression. The associations between clinical scores, treatments and biochemical findings suggest a progressive impairment of barrier integrity during the course of the disease.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
These CSF angiogenesis biomarkers are further altered as Parkinson's disease patients progress into more advanced stages with dementia.
“These biomarkers are further altered as patients progress into more advanced PD stages with dementia (288, 474).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [474]
The Results report a higher albumin ratio in advanced than early-stage Parkinson’s disease, supporting a change in a CSF measure with disease stage. But the paper studies albumin transfer and barrier permeability, not CSF angiogenesis biomarkers, and does not establish an alteration associated with dementia (Results and Discussion; page unavailable). (LLM, conf=0.84)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990 · see citing works
Neuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984 · see citing works
Merritt, H. H., FREMONT-SMITH, F., & Ayer, J. B. (1938) · The American Journal of the Medical Sciences · doi:10.1097/00000441-193804000-00024 · Cited by 876 · see citing works
A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking
Teunissen, C. E., Petzold, A., Bennett, J. L., Berven, F. S., Brundin, L., Comabella, M., Franciotta, D., Frederiksen, J. L., Fleming, J. O., Furlan, R., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c47cc2 · Cited by 845 · see citing works
Self-citationBlood–brain barrier dysfunction in parkinsonian midbrain in vivo
Kortekaas, R., Leenders, K. L., van Oostrom, J. C. H., Vaalburg, W., Bart, J., Willemsen, A. T. M., & Hendrikse, N. H. (2005) · Annals of Neurology · doi:10.1002/ana.20369 · Cited by 733 · see citing works
The Blood-Brain Barrier in Brain Homeostasis and Neurological Diseases
Weiss, N., Miller, F., Cazaubon, S., & Couraud, P.-O. (2009) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2008.10.022 · Cited by 731 · see citing works
Red Blood Cells Are the Major Source of Alpha-Synuclein in Blood
Barbour, R., Kling, K., Anderson, J. P., Banducci, K., Cole, T. A., Diep, L., Fox, M., Goldstein, J. M., Soriano, F., Seubert, P. A., et al. (2008) · Neurodegenerative Diseases · doi:10.1159/000112832 · Cited by 527 · see citing works
Dynamics of brain-derived proteins in cerebrospinal fluid
Reiber, H. (2001) · Clinica Chimica Acta · doi:10.1016/s0009-8981(01)00573-3 · Cited by 512 · see citing works
THE SIGNIFICANCE OF THE LEWY BODY IN THE DIAGNOSIS OF IDIOPATHIC PARKINSON'S DISEASE
Gibb, W. R. G., & Lees, A. J. (1989) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.1989.tb01147.x · Cited by 317 · see citing works
The natural history of treated Parkinson's disease in an incident, community based cohort
Evans, J., Mason, S., Williams‐Gray, C. H., Foltynie, T., Brayne, C., Robbins, T. W., & Barker, R. (2011) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2011.240366 · Cited by 235 · see citing works
6-Hydroxydopamine-induced alterations in blood-brain barrier permeability
Carvey, P. M., Zhao, C. H., Hendey, B., Lum, H., Trachtenberg, J., Desai, B. S., Snyder, J., Zhu, Y. G., & Ling, Z. D. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04281.x · Cited by 218 · see citing works
Polymorphism in the P-glycoprotein drug transporter MDR1 gene
Droździk, M., Białecka, M. A., liwiec, K. M., Honczarenko, K., Stankiewicz, J., & Sych, Z. (2003) · Pharmacogenetics · doi:10.1097/00008571-200305000-00004 · Cited by 207 · see citing works
L’Episcopo, F., Tirolo, C., Testa, N., Caniglia, S., Morale, M. C., Cossetti, C., D’Adamo, P., Zardini, E., Andreoni, L., Ihekwaba, A., et al. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.10.023 · Cited by 186 · see citing works
Self-citationTeunissen, C. E., Petzold, A., Bennett, J. L., Berven, F. S., Brundin, L., Comabella, M., Franciotta, D. M., Federiksen, J. L., Fleming, J. O., Furlan, R., et al. (2010) · Journal of Laboratory Medicine · doi:10.1515/jlm.2010.001 · Cited by 162 · see citing works
Self-citationWestin, J. E., Lindgren, H. S., Gardi, J. E., Nyengaard, J. R., Brundin, P., Mohapel, P., & Cenci, M. A. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.0944-06.2006 · Cited by 130 · see citing works
Downregulation of cerebrospinal fluid production in patients with chronic hydrocephalus
Silverberg, G. D., Huhn, S. L., Jaffe, R., Chang, S. D., Saul, T., Heit, G., Essen, A. V., & Rubenstein, E. (2002) · Journal of neurosurgery · doi:10.3171/jns.2002.97.6.1271 · Cited by 105 · see citing works
Thompson, E. J. (1995) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.59.4.349 · Cited by 54 · see citing works
An active transport system in the blood–brain barrier may reduce levodopa availability
Hawkins, R. A., Mokashi, A. S., & Simpson, I. A. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.04.008 · Cited by 52 · see citing works
Integrity of the blood–cerebrospinal fluid barrier in early Parkinson's disease
Häussermann, P., Kuhn, W., Przuntek, H., & Müller, T. H. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01574-9 · Cited by 42 · see citing works
Fisone, G., Snyder, G. L., Aperia, A. C., & Greengard, P. (1998) · Molecular Medicine · doi:10.1007/bf03401922 · Cited by 26 · see citing works
Levodopa availability improves with progression of Parkinson’s disease
Woitalla, D., Goetze, O., Kim, J. I., Nikodem, A., Schmidt, W. E., Przuntek, H., & Müller, T. H. (2006) · Journal of Neurology · doi:10.1007/s00415-006-0207-y · Cited by 21 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076 · see citing works
The Neurovascular Unit Coming of Age: A Journey through Neurovascular Coupling in Health and Disease
Iadecola, C. (2017) · Neuron · doi:10.1016/j.neuron.2017.07.030 · Cited by 2,480 · see citing works
Blood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,294 · see citing works
Saraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.044 · Cited by 1,609 · see citing works
Nanomaterial-based blood-brain-barrier (BBB) crossing strategies
Xie, J., Shen, Z., Anraku, Y., Kataoka, K., & Chen, X. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119491 · Cited by 604 · see citing works
The gut-brain axis: is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis?
Houser, M. C., & Tansey, M. G. (2017) · npj Parkinson's Disease · doi:10.1038/s41531-016-0002-0 · Cited by 588 · see citing works
Parkinson’s Disease-Related Proteins PINK1 and Parkin Repress Mitochondrial Antigen Presentation
Matheoud, D., Sugiura, A., Bellemare-Pelletier, A., Laplante, A., Rondeau, C., Chemali, M., Fazel, A., Bergeron, J. J., Trudeau, L.-E., Burelle, Y., et al. (2016) · Cell · doi:10.1016/j.cell.2016.05.039 · Cited by 582 · see citing works
Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics
Petersen, M. A., Ryu, J. K., & Akassoglou, K. (2018) · Nature reviews. Neuroscience · doi:10.1038/nrn.2018.13 · Cited by 527 · see citing works
What does plasma CRP tell us about peripheral and central inflammation in depression?
Felger, J. C., Haroon, E., Patel, T. A., Goldsmith, D. R., Wommack, E. C., Woolwine, B. J., Le, N.-A., Feinberg, R., Tansey, M. G., & Miller, A. H. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0096-3 · Cited by 448 · see citing works
Lochhead, J. J., Yang, J., Ronaldson, P. T., & Davis, T. P. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00914 · Cited by 445 · see citing works
Age-associated Physiological and Pathological Changes at the Blood-Brain Barrier: A Review
Erdő, F., Denes, L., & de Lange, E. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16679420 · Cited by 426 · see citing works
Striatal Blood–Brain Barrier Permeability in Parkinson'S Disease
Gray, M. T., & Woulfe, J. M. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.32 · Cited by 409 · see citing works
Microglia–blood vessel interactions: a double-edged sword in brain pathologies
Dudvarski Stankovic, N., Teodorczyk, M., Ploen, R., Zipp, F., & Schmidt, M. H. H. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1524-y · Cited by 301 · see citing works
The Role of Innate and Adaptive Immunity in Parkinson's Disease
Kannarkat, G. T., Boss, J. M., & Tansey, M. G. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130250 · Cited by 324 · see citing works
Cenci, M. A. (2014) · Frontiers in Neurology · doi:10.3389/fneur.2014.00242 · Cited by 239 · see citing works
Sánchez-Guajardo, V., Barnum, C. J., Tansey, M. G., & Romero‐Ramos, M. (2013) · ASN NEURO · doi:10.1042/an20120066 · Cited by 237 · see citing works
Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease
Zhang, Q.-S., Heng, Y., Mou, Z., Huang, J.-Y., Yuan, Y.-H., & Chen, N.-H. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.49 · Cited by 208 · see citing works
Penetration of PFASs Across the Blood Cerebrospinal Fluid Barrier and Its Determinants in Humans
Wang, J., Pan, Y., Cui, Q., Yao, B., Wang, J., & Dai, J. (2018) · Environmental Science & Technology · doi:10.1021/acs.est.8b04550 · Cited by 192 · see citing works
Cerebrospinal fluid β‐glucocerebrosidase activity is reduced in parkinson's disease patients
Parnetti, L., Paciotti, S., Eusebi, P., Dardis, A., Zampieri, S., Chiasserini, D., Tasegian, A., Tambasco, N., Bembi, B., Calabresi, P., et al. (2017) · Movement Disorders · doi:10.1002/mds.27136 · Cited by 178 · see citing works
Blood–brain barrier alterations and their impact on Parkinson’s disease pathogenesis and therapy
Lau, K., Kotzur, R., & Richter, F. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00430-z · Cited by 165 · see citing works
Increased CSF biomarkers of angiogenesis in Parkinson disease
Janelidze, S., Lindqvist, D., Francardo, V., Hall, S., Zetterberg, H., Blennow, K., Adler, C. H., Beach, T. G., Serrano, G. E., van Westen, D., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000002151 · Cited by 150 · see citing works
Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease
Hsiao, H., Chiu, F., Chen, C., Wu, Y., Chen, H., Chen, Y., Kuo, H., & Chern, Y. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu151 · Cited by 135 · see citing works
The current state of biomarkers of mild traumatic brain injury
Kim, H., Tsao, J. W., & Stanfill, A. G. (2018) · JCI Insight · doi:10.1172/jci.insight.97105 · Cited by 127 · see citing works
Elabi, O. F., Gaceb, A., Carlsson, R., Padel, T., Soylu-Kucharz, R., Cortijo, I., Li, W., Li, J., & Paul, G. (2021) · Scientific Reports · doi:10.1038/s41598-020-80889-8 · Cited by 127 · see citing works
Chung, Y. C., Shin, W.-H., Baek, J. Y., Cho, E. J., Baik, H. H., Kim, S. R., Won, S.-Y., & Jin, B. K. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2015.100 · Cited by 126 · see citing works
Jacquet, A. D. R., Alpaugh, M., Denis, H. L., Tancredi, J. L., Boutin, M., Decaestecker, J., Beauparlant, C., Herrmann, L., Saint-Pierre, M., Parent, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39038-8 · Cited by 114 · see citing works
CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients
Skillbäck, T. B., Delsing, L., Synnergren, J., Mattsson, N., Janelidze, S., Nägga, K., Kilander, L., Hicks, R., Wimo, A. B., Winblad, B. G., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.06.028 · Cited by 123 · see citing works
Lan, G., Wang, P., Chan, R. B., Liu, Z., Yu, Z., Liu, X., Yang, Y., & Zhang, J. (2022) · Glia · doi:10.1002/glia.24109 · Cited by 122 · see citing works
Fluid biomarkers in frontotemporal dementia: past, present and future
Swift, I. J., Sogorb-Esteve, A., Heller, C., Synofzik, M., Otto, M., Graff, C., Galimberti, D., Todd, E., Heslegrave, A. J., van der Ende, E. L., et al. (2021) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-323520 · Cited by 122 · see citing works
Cerebrospinal fluid biomarkers for Parkinson's disease - a systematic review
Andersen, A. D., Binzer, M., Stenager, E., & Gramsbergen, J. B. (2016) · Acta Neurologica Scandinavica · doi:10.1111/ane.12590 · Cited by 116 · see citing works
Engineered nanomaterials that exploit blood-brain barrier dysfunction for delivery to the brain
Wu, J. R., Hernández, Y. M., Miyasaki, K. F., & Kwon, E. J. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114820 · Cited by 103 · see citing works
Deo, A. K., Theil, F., & Nicolas, J.-M. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300570z · Cited by 103 · see citing works
Distinct Patterns of Cerebral Extravasation by Evans Blue and Sodium Fluorescein in Rats
Yen, L. F., Wei, V. C., Kuo, E. Y., & Lai, T. W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068595 · Cited by 101 · see citing works
Microvascular Changes in Parkinson’s Disease- Focus on the Neurovascular Unit
Paul, G., & Elabi, O. F. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.853372 · Cited by 97 · see citing works
Cerebrospinal fluid proteomics implicates the granin family in Parkinson’s disease
Rotunno, M. S., Lane, M., Zhang, W., Wolf, P., Oliva, P., Viel, C., Wills, A.-M., Alcalay, R. N., Scherzer, C. R., Shihabuddin, L. S., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-59414-4 · Cited by 94 · see citing works
Chung, Y. C., Kim, Y.-S., Bok, E., Yune, T. Y., Maeng, S., & Jin, B. K. (2013) · Mediators of Inflammation · doi:10.1155/2013/370526 · Cited by 94 · see citing works
Eryptosis as a marker of Parkinson's disease
Pretorius, E., Swanepoel, A. C., Buys, A. V., Vermeulen, N., Duim, W., & Kell, D. B. (2014) · Aging · doi:10.18632/aging.100695 · Cited by 91 · see citing works
Gut Inflammation in Association With Pathogenesis of Parkinson’s Disease
Chen, Q.-Q., Haikal, C., Li, W., & Li, J. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00218 · Cited by 88 · see citing works
Blood–Brain Barrier and Neurodegenerative Diseases—Modeling with iPSC-Derived Brain Cells
Wu, Y., Sonninen, T.-M., Peltonen, S., Koıstınaho, J., & Lehtonen, Š. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147710 · Cited by 88 · see citing works
Fang, X. (2015) · International Journal of Neuroscience · doi:10.3109/00207454.2015.1096271 · Cited by 84 · see citing works
COVID-19: dealing with a potential risk factor for chronic neurological disorders
Schirinzi, T., Landi, D., & Liguori, C. (2020) · Journal of Neurology · doi:10.1007/s00415-020-10131-y · Cited by 76 · see citing works
Bors, L. A., Tóth, K., Tóth, E. Z., Bajza, Á., Csorba, A., Szigeti, K., Máthé, D., Perlaki, G., Orsi, G., Tóth, G. K., et al. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.03.001 · Cited by 75 · see citing works
Peripheral Immunity, Immunoaging and Neuroinflammation in Parkinson’s Disease
Kuštrimović, N. Z., Marino, F., & Cosentino, M. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666181009161048 · Cited by 74 · see citing works
Modarres, H. P., Janmaleki, M., Novin, M., Saliba, J., Moussa, F. E. H., Charan, M. R., Seyfoori, A., SadAbadi, H., Vandal, M., Nguyen, M. D., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.01.024 · Cited by 73 · see citing works
Deciphering albumin-directed drug delivery by imaging
Hu, H., Quintana, J. M., Weissleder, R., Parangi, S., & Miller, M. A. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114237 · Cited by 70 · see citing works
Cerri, S., Greco, R., Levandis, G., Ghezzi, C., Mangione, A. S., Armentero, M., Bonizzi, A., Avanzini, M. A., Maccario, R., & Blandini, F. (2015) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0023 · Cited by 70 · see citing works
Armentero, M., Cerri, S., & Blandini, F. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00232 · Cited by 70 · see citing works
The molecular anatomy and functions of the choroid plexus in healthy and diseased brain
Kratzer, I., Ek, C. J., & Stolp, H. B. (2020) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2020.183430 · Cited by 67 · see citing works
Exploiting BBB disruption for the delivery of nanocarriers to the diseased CNS
Umlauf, B. J., & Shusta, E. V. (2019) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2019.01.013 · Cited by 67 · see citing works
Unique signatures of stress-induced senescent human astrocytes
Simmnacher, K., Krach, F., Schneider, Y., Alecu, J. E., Mautner, L., Klein, P., Roybon, L., Prots, I., Xiang, W., & Winner, B. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113466 · Cited by 63 · see citing works
Blood-brain barrier models: Rationale for selection
Hanafy, A. S., Dietrich, D., Fricker, G., & Lamprecht, A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113859 · Cited by 58 · see citing works
Blood–brain barrier opening with focused ultrasound in experimental models of Parkinson's disease
Karakatsani, M. E., Blesa, J., & Konofagou, E. E. (2019) · Movement Disorders · doi:10.1002/mds.27804 · Cited by 57 · see citing works
Yang, W., Chang, Z., Que, R., Weng, G., Deng, B., Wang, T., Huang, Z., Xie, F., Wei, X., Yang, Q., et al. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00053 · Cited by 55 · see citing works
Mancini, S., Minniti, S., Gregori, M., Sancini, G., Cagnotto, A., Couraud, P., Ordóñez‐Gutiérrez, L., Wandosell, F. G., Salmona, M., & Re, F. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.09.003 · Cited by 54 · see citing works
Parkinson's and Lewy body dementia CSF biomarkers
Parnetti, L., Paciotti, S., Farotti, L., Bellomo, G., Sepe, F. N., & Eusebi, P. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.04.078 · Cited by 54 · see citing works
Homologous HSV1 and alpha-synuclein peptides stimulate a T cell response in Parkinson's disease
Caggiu, E., Paulus, K. S., Galleri, G., Arru, G., Manetti, R., Sechi, G., & Sechi, L. A. (2017) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2017.06.004 · Cited by 52 · see citing works
Gorlé, N., Blaecher, C., Bauwens, E., Vandendriessche, C., Balusu, S., Vandewalle, J., Van Cauwenberghe, C., Van Wonterghem, E., Van Imschoot, G., Liu, C., et al. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.12.010 · Cited by 49 · see citing works
Cerebrospinal fluid biomarkers profile of idiopathic normal pressure hydrocephalus
Schirinzi, T., Sancesario, G. M., Lazzaro, G. D., D’Elia, A., Imbriani, P., Scalise, S., & Pisani, A. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1842-z · Cited by 49 · see citing works
Self-citationGoldim, M. P. D. S., Danielski, L. G., Rodrigues, J. F., Joaquim, L. D. S., Garbossa, L., de Oliveira, A. N., Metzker, K. L. L., Giustina, A. D., Cardoso, T., Barichello, T., et al. (2018) · Microvascular Research · doi:10.1016/j.mvr.2018.12.001 · Cited by 48 · see citing works
Katayama, T., Sawada, J., Takahashi, K., & Yahara, O. (2020) · Brain Sciences · doi:10.3390/brainsci10070466 · Cited by 48 · see citing works
Acylated Ghrelin as a Multi-Targeted Therapy for Alzheimer's and Parkinson's Disease
Reich, N., & Hölscher, C. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.614828 · Cited by 48 · see citing works
“Unsurprisingly, in line with the encouraged cerebral trespassing of lymphocytes, BBB leakage has been confirmed in the brains of PD patients (Kortekaas et al., 2005; Pisani et al., 2012).”
BackgroundHuman serum albumin in neurodegeneration
Shojai, S., Rohani, S., Moosavi‐Movahedi, A. A., & Habibi-Rezaei, M. (2022) · Reviews in the Neurosciences · doi:10.1515/revneuro-2021-0165 · Cited by 47 · see citing works
Bellomo, G., Bologna, S., Cerofolini, L., Paciotti, S., Gatticchi, L., Ravera, E., Parnetti, L., Fragai, M., & Luchinat, C. (2019) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.9b02381 · Cited by 47 · see citing works
Schirinzi, T., Sancesario, G. M., Ialongo, C., Imbriani, P., Madeo, G., Toniolo, S., Martorana, A., & Pisani, A. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00086 · Cited by 45 · see citing works
Self-citationBlood-Brain Barrier Dysfunction in Small Vessel Disease Related Intracerebral Hemorrhage
Freeze, W. M., Jacobs, H. I. L., Schreuder, F. H. B. M., van Oostenbrugge, R. J., Backes, W. H., Verhey, F. R. J., & Klijn, C. J. M. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00926 · Cited by 45 · see citing works
Dietary cholesterol, fats and risk of Parkinson's disease in the Singapore Chinese Health Study
Tan, L., Methawasin, K., Tan, E., Tan, J. H., Au, W., Yuan, J., & Koh, W. (2015) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-310065 · Cited by 42 · see citing works
Molecular and Cellular Interactions in Pathogenesis of Sporadic Parkinson Disease
Долгачева, Л. П., Зинченко, В. П., & Goncharov, N. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113043 · Cited by 41 · see citing works
Wong, Y. Y., Wu, C., Yu, D., Kim, E., Wong, M., Elez, R., Zebarth, J., Ouk, M., Tan, J., Liao, J., et al. (2022) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2022.06.004 · Cited by 41 · see citing works
Microbiome–gut–brain dysfunction in prodromal and symptomatic Lewy body diseases
Ryman, S. G., Vakhtin, A. A., Richardson, S. P., & Lin, H. C. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11461-9 · Cited by 38 · see citing works
Li, F., Weng, G., Zhou, H., Zhang, W., Deng, B., Luo, Y., Xi, T., Deng, M., Guo, H., Zhu, S., et al. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1322228 · Cited by 37 · see citing works
α-Synuclein and Noradrenergic Modulation of Immune Cells in Parkinson’s Disease Pathogenesis
Butkovich, L. M., Houser, M. C., & Tansey, M. G. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00626 · Cited by 37 · see citing works
Zhang, Y., Fan, F., Zeng, G., Zhou, L., Zhang, Y., Zhang, J., He, J., Zhang, T., Su, D., Yang, C., et al. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16680221 · Cited by 36 · see citing works
Wu, H., Brown, E. V., Acharya, N. K., Appelt, D. M., Marks, A., Nagele, R. G., & Venkataraman, V. (2016) · Brain Research · doi:10.1016/j.brainres.2016.02.026 · Cited by 35 · see citing works
Nanotechnology to Overcome Blood–Brain Barrier Permeability and Damage in Neurodegenerative Diseases
Jiménez, A., Estudillo, E., Guzmán‐Ruiz, M. A., Herrera, N., Victoria-Acosta, G., Cortés-Malagón, E. M., & López-Ornelas, A. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17030281 · Cited by 34 · see citing works
Increased albumin CSF/serum ratio in dementia with Lewy bodies
Llorens, F., Schmitz, M., Gloeckner, S. F., Kaerst, L., Hermann, P., Schmidt, C., Varges, D., & Zerr, I. (2015) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2015.10.011 · Cited by 34 · see citing works
Chi, H., Guan, Y., Li, F., & Chen, Z. (2019) · Cell Transplantation · doi:10.1177/0963689719891134 · Cited by 34 · see citing works
The role of glia in Parkinson's disease: Emerging concepts and therapeutic applications
Kuter, K. Z., Cenci, M. A., & Carta, A. R. (2020) · Progress in brain research · doi:10.1016/bs.pbr.2020.02.004 · Cited by 30 · see citing works
Relationship of Cerebrospinal Fluid Vitamin B12 Status Markers With Parkinson's Disease Progression
Christine, C. W., Auinger, P., Saleh, N., Tian, M., Bottiglieri, T., Arning, E., Tran, N. K., Ueland, P. M., Green, R., & the Parkinson Study Group—DATATOP Investigators (2020) · Movement Disorders · doi:10.1002/mds.28073 · Cited by 30 · see citing works
Sommonte, F., Arduino, I., Racaniello, G. F., Lopalco, A., Lopedota, A. A., & Denora, N. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.08.029 · Cited by 29 · see citing works
Towards early detection of neurodegenerative diseases: A gut feeling
Makdissi, S., Parsons, B., & Cara, F. D. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1087091 · Cited by 27 · see citing works
The Functional Roles and Applications of Immunoglobulins in Neurodegenerative Disease
Sim, K.-Y., Im, K. C., & Park, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155295 · Cited by 24 · see citing works
Karch, A., Manthey, H. G., Ponto, C., Hermann, P., Heinemann, U., Schmidt, C., & Zerr, I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084405 · Cited by 23 · see citing works
Tate, D. F., Dennis, E. L., Adams, J. T., Adamson, M. M., Belanger, H. G., Bigler, E. D., Bouchard, H. C., Clark, A. L., Delano‐Wood, L., Disner, S. G., et al. (2021) · Brain Imaging and Behavior · doi:10.1007/s11682-020-00423-2 · Cited by 22 · see citing works
Ceruloplasmin Deamidation in Neurodegeneration: From Loss to Gain of Function
Zanardi, A., & Alessio, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020663 · Cited by 22 · see citing works
Substance P and its tachykinin NK1 receptor: a novel neuroprotective target for Parkinson′s disease
Vink, R., & Thornton, E. (2015) · Neural Regeneration Research · doi:10.4103/1673-5374.165505 · Cited by 21 · see citing works
Marques, D., Moura-Louro, D., Silva, I. P., Matos, S., dos Santos, C. N., & Figueira, I. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105836 · Cited by 20 · see citing works
The Breakdown of Neurovascular Barriers: Molecular Mechanisms of Tight Junction Dysfunction
Gopal, S. S., Kaur, M., Lanzkron, S., & Srivastava, A. K. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05592-z · Cited by 19 · see citing works
Nanomedicine against Alzheimer’s and Parkinson’s Disease
Tandon, A., Singh, S. J., & Chaturvedi, R. K. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666201021140904 · Cited by 19 · see citing works
Nakagawa, Y., & Yamada, S. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-022-01234-3 · Cited by 19 · see citing works
Nakagawa, Y., & Yamada, S. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107455 · Cited by 17 · see citing works
Liu, Y., Gou, M., & Guo, X. (2023) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2205115 · Cited by 17 · see citing works
Hou, J., Liu, Q., Li, Y., Sun, H., & Zhang, J. (2014) · BioMed Research International · doi:10.1155/2014/850493 · Cited by 17 · see citing works
Gan, J., Yang, X., Zhang, G., Li, X., Liu, S., Zhang, W., & Ji, Y. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1088140 · Cited by 16 · see citing works
Multifunctional Nanoparticles for Successful Targeted Drug Delivery across the Blood-Brain Barrier
Vieira, D. B., & Gamarra, L. F. (2018) · InTech eBooks · doi:10.5772/intechopen.76922 · Cited by 16 · see citing works
Fernandes, M., Maio, S., Eusebi, P., Placidi, F., Izzi, F., Spanetta, M., Masi, C. D., Lupo, C., Calvello, C., Nuccetelli, M., et al. (2023) · SLEEP · doi:10.1093/sleep/zsad198 · Cited by 15 · see citing works
Kilgore, M. O., & Hubbard, W. B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25010642 · Cited by 15 · see citing works
Gao, M., Zhang, C., Gao, L., Sun, S., Song, L., & Liu, S. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e12671 · Cited by 15 · see citing works
Do Bacterial Outer Membrane Vesicles Contribute to Chronic Inflammation in Parkinson’s Disease?
Koukoulis, T. F., Beauchamp, L. C., Kaparakis‐Liaskos, M., McQuade, R. M., Purnianto, A., Finkelstein, D. I., Barnham, K. J., & Vella, L. J. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-230315 · Cited by 14 · see citing works
Gut microbiota and inflammation in Parkinson’s disease: Pathogenetic and therapeutic insights
Guo, T., & Chen, L. (2022) · European Journal of Inflammation · doi:10.1177/1721727x221083763 · Cited by 14 · see citing works
Phan, J.-A., Landau, A. M., Jakobsen, S., Wong, D. F., & GJEDDE, A. H. (2017) · Scientific Reports · doi:10.1038/s41598-017-16020-1 · Cited by 14 · see citing works
- Authors
- Pisani, V., Stefani, A., Pierantozzi, M., Natoli, S., Stanzione, P., Franciotta, D., & Pisani, A.
- Affiliations
- University of Rome Tor Vergata (IT)
- Fondazione Istituto Neurologico Nazionale Casimiro Mondino (IT)
- Corresponding author
- Pisani, Antonio
- ORCID
- Venue
- Journal of Neuroinflammation
- Published
- 2012-08-08
- Volume
- 9
- Issue
- 1
- Pages
- 188-188
- ISSN
- 1742-2094 (ISSN-L)
- PMC
- PMC3441323
- OpenAlex
- W2155862034
- Cited by
- 158
- References
- 21
- Citations by year
- 2026: 11 · 2025: 14 · 2024: 15 · 2023: 7 · 2022: 11 · 2021: 11 · 2020: 18 · 2019: 9 · 2018: 17 · 2017: 9 · 2016: 10 · 2015: 12 · 2014: 6 · 2013: 7 · 2012: 1
- FWCI
- 5.12
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Journal of Neuroinflammation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Istituto Nazionale per l'Assicurazione Contro Gli Infortuni sul Lavoro
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Cerebrospinal fluid and hydrocephalus
- Keywords
- Parkinson's disease, blood-brain barrier permeability, blood-CSF barrier, albumin ratio, cerebrospinal fluid albumin, disease progression, Hoehn-Yahr staging, dopaminergic therapy, barrier dysfunction
- MeSH terms
- Adult, Aged, Aged, 80 and over, Albumins, Blood-Brain Barrier, Female, Humans, Male, Middle Aged, Parkinson Disease, Severity of Illness Index, Cohort Studies, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
